Drugs / MVA-mBN120B
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00623259 | May 2008 → Feb 2009 | HIV infectious disease | Bavarian Nordic | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVA-mBN120B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00623259 ↗ |
| Modality | Vaccine | “recombinant MVA-HIV multiantigen vaccine” NCT00623259 ↗ |
| Route | Subcutaneous | “The vaccine will be administered subcutaneously.” NCT00623259 ↗ |